clinical trial · NCT06846515
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
GoutArthritis, GoutyHyperuricemiaGout ChronicAR882 50 mgAR882 75 mgPlacebo
brief summary
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
started
Mar 11, 2025
primary completion
Apr 1, 2026
completion
Apr 1, 2026
last updated
Sep 17, 2025
official title
A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol